Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ovarian cancer, advanced' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 131 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Malingre, MM; Rosing, H; Koopman, FJ; Schellens, JHM; Beijnen, JH
      Performance of the analytical assays of paclitaxel, docetaxel, and cyclosporin a in a routine hospital laboratory setting

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    2. Ferguson, WS; Harris, MB; Goorin, AM; Gebhardt, MC; Link, MP; Shochat, SJ; Siegal, GP; Devidas, M; Grier, HE
      Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group trial

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    3. Orr, JW; Roland, PY; Orr, PJ; Bolen, DD; Hutcheson, SL
      Subspecialty training: does it affect the outcome of women treated for a gynecologic malignancy?

      CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
    4. Ripamonti, C; Twycross, R; Baines, M; Bozzetti, F; Capri, S; De Conno, F; Gemlo, B; Hunt, TM; Krebs, HB; Mercadante, S; Schaerer, R; Wilkinson, P
      Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer

      SUPPORTIVE CARE IN CANCER
    5. Pignata, S; Ballatori, E; Favalli, G; Scambia, G
      Quality of life: Gynaecological cancers

      ANNALS OF ONCOLOGY
    6. Legendre, H; Vanhuyse, F; Caroli-Bosc, FX; Pector, JC
      Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    7. Yokoyama, Y; Kaji, H; Kondoh, H; Takeuchi, E; Yamasaki, Y; Inui, Y
      Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin

      GYNECOLOGIC AND OBSTETRIC INVESTIGATION
    8. Nardi, M; De Marco, S; Fabi, A; Aloe, A; Magnani, E; Pacetti, U; Carlini, P; Ruggeri, EM; Cognetti, F
      Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    9. Fujiwara, K; Yamauchi, H; Suzuki, S; Ishikawa, H; Tanaka, Y; Fujiwara, M; Kohno, I
      The platelet-sparing effect of paclitaxel is not related to changes in thepharmacokinetics of carboplatin

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    10. Kintzel, PE
      Anticancer drug-induced kidney disorders - Incidence, prevention and management

      DRUG SAFETY
    11. Gadducci, A; Landoni, F; Sartori, E; Maggino, T; Zola, P; Gabriele, A; Rossi, R; Cosio, S; Fanucchi, A; Tisi, G
      Analysis of treatment failures and survival of patients with Fallopian tube carcinoma: A cooperation task force (CTF) study

      GYNECOLOGIC ONCOLOGY
    12. Markman, M; Spriggs, D; Burger, RA; Carson, LF; Lentz, SS; Gallion, H
      Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: A Gynecologic Oncology Group study

      GYNECOLOGIC ONCOLOGY
    13. Giannice, R; Susini, T; Ferrandina, G; Poerio, A; Margariti, PA; Carminati, R; Marana, E; Mancuso, S; Scambia, G
      Systematic pelvic and aortic lymphadenectomy in elderly gynecologic oncologic patients

      CANCER
    14. Legendre, H; Van Huyse, F; Caroli-Bosc, FX; Pector, JC
      Intestinal obstruction in patients with malignancy: results of palliative surgery.

      ANNALES DE CHIRURGIE
    15. Perez-Calvo, J; Martinez-Aguillo, M; Garcia-Rayo, S; Cajal, TRY; Santisteban, M; Ordonez, JM; Inoges, S; Subira, ML; Martin-Algarra, S; Brugarolas, A
      Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support

      ACTA HAEMATOLOGICA
    16. Vergote, I; de Wever, I; Tjalma, W; Van Gramberen, M; Decloedt, J; Van Dam, P
      Interval debulking surgery: An alternative for primary surgical debulking?

      SEMINARS IN SURGICAL ONCOLOGY
    17. Scheulen, ME; Hilger, RA; Oberhoff, C; Casper, J; F'reund, M; Josten, KM; Bornhauser, M; Ehninger, G; Berdel, WE; Baumgart, J; Harstrick, A; Bojko, P; Wolf, HH; Schindler, AE; Seeber, S
      Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies

      CLINICAL CANCER RESEARCH
    18. Poveda, A
      Advanced ovarian cancer: update, remarks and conclusions on optimal therapy

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    19. Corson, DT; Meares, CF
      Efficient multigram synthesis of the bifunctional chelating agent (S)-1-p-isothiocyanatobenzyl-diethylenetetraminepentaacetic acid

      BIOCONJUGATE CHEMISTRY
    20. Matsumoto, Y; Deguchi, M; Ishiko, O; Ogita, S
      Retrospective study of the prognostic factors of remission induction for single-agent chemotherapy with cisplatin in advanced epithelial ovarian cancer

      ONCOLOGY REPORTS
    21. Takeshima, N; Hasumi, K
      Treatment of fallopian tube cancer - Review of the literature

      ARCHIVES OF GYNECOLOGY AND OBSTETRICS
    22. Capizzi, RL; Oster, W
      Chemoprotective and radioprotective effects of amifostine: An update of clinical trials

      INTERNATIONAL JOURNAL OF HEMATOLOGY
    23. Rischin, D; Boyer, M; Smith, J; Millward, M; Michael, M; Bishop, J; Zalcberg, J; Davison, J; Emmett, E; McClure, B
      A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

      ANNALS OF ONCOLOGY
    24. Fizazi, K; Zelek, L
      Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms

      ANNALS OF ONCOLOGY
    25. Katsumata, N; Tsunematsu, R; Tanaka, K; Terashima, Y; Ogita, S; Hoshiai, H; Kohno, I; Hirabayashi, K; Yakushiji, M; Noda, K; Taguchi, T
      A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese Cooperative Study

      ANNALS OF ONCOLOGY
    26. Bennett, CL; Stinson, TJ
      Comparing cost-effectiveness analyses for the clinical oncology setting: The example of the Gynecologic Oncology Group 111 trial

      CANCER INVESTIGATION
    27. Funaro, A; Horenstein, AL; Santoro, P; Cinti, C; Gregorini, A; Malavasi, F
      Monoclonal antibodies and therapy of human cancers

      BIOTECHNOLOGY ADVANCES
    28. Massacesi, C; Bascioni, R; Cellerino, R; Scartozzi, M; Bracci, R; Alessandroni, P; Antognoli, S; Ciavattini, A; De Nictolis, M; Piga, A
      Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer

      JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    29. Wong, C; Dai, ZM; Lele, SB; Natarajan, N
      Comparison of CA 125 after three courses of chemotherapy and results of second-look surgery

      EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    30. Senapad, S; Neungton, S; Thirapakawong, C; Suphanit, I; Hangsubcharoen, M; Thamintorn, K
      Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer

      ANTICANCER RESEARCH
    31. Buntzel, J; Glatzel, M; Frohlich, D; Kuttner, K
      Cytoprotection as a new supportive strategy in the treatment of solid tumors

      SECONDARY NEOPLASIAS FOLLOWING CHEMOTHERAPY, RADIOTHERAPY, AND IMMUNOSUPPRESSION
    32. Blasiak, J; Smolarz, B; Kubryn, I; Kulig, A; Dziki, A; Ulanska, J; Pander, B
      Plasminogen activator inhibitor-1 (PAI-1) level and 4G/5G genetic polymorphism in patients with colorectal cancer

      EXPERIMENTAL ONCOLOGY
    33. Israel, VP; Garcia, AA; Roman, L; Muderspach, L; Burnett, A; Jeffers, S; Muggia, FM
      Phase II study of liposomal doxorubicin in advanced gynecologic cancers

      GYNECOLOGIC ONCOLOGY
    34. Rose, PG; Lappas, PT
      Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials

      GYNECOLOGIC ONCOLOGY
    35. Hallfeldt, K; Schmidbauer, S; Trupka, A
      Laparoscopic loop colostomy for advanced ovarian cancer, rectal cancer, and rectovaginal fistulas

      GYNECOLOGIC ONCOLOGY
    36. Yamashiro, C; Yanagihara, T; Hata, T
      Regression of liver metastases after high-dose chemotherapy and peripheral-blood progenitor-cell support in Stage IV ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
    37. Giaccone, G
      Clinical perspectives on platinum resistance

      DRUGS
    38. Chatelut, E; Canal, P; Bugat, R
      Pharmacokinetics and dose adjustment of carboplatin

      BULLETIN DU CANCER
    39. Blasiak, J; Smolarz, B
      Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphismis not associated with breast cancer

      ACTA BIOCHIMICA POLONICA
    40. Yamamoto, K; Yajima, A; Terashima, Y; Nozawa, S; Taketani, Y; Yakushiji, M; Noda, K
      Phase II clinical study on the effects of recombinant human interleukin-3 on thrombocytopenia after chemotherapy for advanced ovarian cancer

      JOURNAL OF IMMUNOTHERAPY
    41. McKeage, MJ; Haddad, GG; Ding, L; Galettis, P; Screnci, D; Zhuang, L; Baguley, BC
      Neuroprotective interactions in rats between paclitaxel and cisplatin

      ONCOLOGY RESEARCH
    42. Gross, M; Hiesse, C; Kriaa, F; Goldwasser, F
      Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine

      ANTI-CANCER DRUGS
    43. Bertelsen, K; Grenman, S; Rustin, GJS
      How long should first-line chemotherapy continue?

      ANNALS OF ONCOLOGY
    44. du Bois, A; Neijt, JP; Thigpen, JT
      First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?

      ANNALS OF ONCOLOGY
    45. Capizzi, RL
      Clinical status and optimal use of amifostine

      ONCOLOGY-NEW YORK
    46. Go, RS; Adjei, AA
      Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

      JOURNAL OF CLINICAL ONCOLOGY
    47. Baekelandt, M; Kristensen, GB; Trope, CG; Nesland, JM; Holm, R
      Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer

      ANTICANCER RESEARCH
    48. Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL
      Evaluation of conflict of interest in economic analyses of new drugs used in oncology

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    49. Bukowski, R
      Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children

      MEDICAL AND PEDIATRIC ONCOLOGY
    50. Capizzi, RL
      Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects

      SEMINARS IN ONCOLOGY
    51. DiPaola, RS; Schuchter, L
      Neurologic protection by amifostine

      SEMINARS IN ONCOLOGY
    52. Feuer, DJ; Broadley, KE; Shepherd, JH; Barton, DPJ
      Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer

      GYNECOLOGIC ONCOLOGY
    53. Magtibay, PM; Perrone, JF; Stanhope, CR; Katzmann, JA; Keeney, GL; Li, HZ
      Flow cytometric DNA analysis of early stage adenocarcinoma of the cervix

      GYNECOLOGIC ONCOLOGY
    54. Magtibay, PM; Perrone, JF; Stanhope, CR; Katzmann, JA; Keeney, GL; Li, HZ
      Flow-cytometric DNA analysis of early stage adenocarcinoma of the cervix

      GYNECOLOGIC ONCOLOGY
    55. Links, M; Lewis, C
      Chemoprotectants - A review of their clinical pharmacology and therapeuticefficacy

      DRUGS
    56. Hospers, GAP; Eisenhauer, EA; de Vries, EGE
      The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

      BRITISH JOURNAL OF CANCER
    57. Kaye, SB
      New drug development: its role in reversing drug resistance

      BRITISH JOURNAL OF CANCER
    58. HOLCOMBE RF; MOORE M
      CYCLOPHOSPHAMIDE, ETOPOSIDE AND HEXAMETHYLMELAMINE (CE-HEX) FOR 5-FLUOROURACIL-RESISTANT METASTATIC COLON-CANCER - A PHASE-II TRIAL

      GI cancer
    59. REUNING U; MAGDOLEN V; WILHELM O; FISCHER K; LUTZ V; GRAEFF H; SCHMITT M
      MULTIFUNCTIONAL POTENTIAL OF THE PLASMINOGEN ACTIVATION SYSTEM IN TUMOR INVASION AND METASTASIS (REVIEW)

      International journal of oncology
    60. LEBWOHL D; CANETTA R
      CLINICAL DEVELOPMENT OF PLATINUM COMPLEXES IN CANCER-THERAPY - AN HISTORICAL-PERSPECTIVE AND AN UPDATE

      European journal of cancer
    61. Berger, K; Fischer, T; Szucs, TD
      Cost-effectiveness analysis of paclitaxel acid cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

      EUROPEAN JOURNAL OF CANCER
    62. Patnaik, A; Doyle, C; Oza, AM
      Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost

      ANTI-CANCER DRUGS
    63. Messori, A; Trippoli, S
      Pharmacoeconomic profile of taxanes in advanced ovarian cancer

      ANTI-CANCER DRUGS
    64. LOKICH J; ANDERSON N
      CARBOPLATIN VERSUS CISPLATIN IN SOLID TUMORS - AN ANALYSIS OF THE LITERATURE

      Annals of oncology
    65. Trope, C; Hogberg, T; Kaern, J; Bertelsen, K; Bjorkholm, E; Boman, K; Himmelmann, A; Horvath, G; Jacobsen, A; Kuoppola, T; Vartianen, J; Lund, B; Onsrud, M; Puistola, U; Salmi, T; Scheistroen, M; Sandvei, R; Simonsen, E; Sorbe, B; Tholander, B; Westberg, R
      Long-term results from a phase II study of single agent paclitaxel (Taxol (R)) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience

      ANNALS OF ONCOLOGY
    66. Spiridonidis, CH; Laufman, LR; Jones, J; Rhodes, VA; Wallace, K; Nicol, S
      Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

      JOURNAL OF CLINICAL ONCOLOGY
    67. Luck, HJ; Scholz, U; Petry, KU; Bohmer, G; Kuhnle, H
      Importance of topotecan in the therapy of ovarian carcinoma, today and tomorrow

      ONKOLOGIE
    68. CVITKOVIC E
      CUMULATIVE TOXICITIES FROM CISPLATIN THERAPY AND CURRENT CYTOPROTECTIVE MEASURES

      Cancer treatment reviews
    69. ZAMAGNI C; MARTONI A; CACCIARI N; GENTILE A; PANNUTI F
      THE COMBINATION OF PACLITAXEL AND CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH STAGE-III AND STAGE IV OVARIAN-CANCER - A PHASE I-II STUDY

      American journal of clinical oncology
    70. TONER GC; GREEN M; BISHOP JF; MCKENDRICK J; CEBON J; SHERIDAN WP; LOCKBAUM P; OBYRNE J; FOX RM
      DOSE-ESCALATION STUDY OF CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH FILGRASTIM SUPPORT - A PHASE-I STUDY

      American journal of clinical oncology
    71. IGNAR DM; ANDREWS JL; WITHERSPOON SM; LERAY JD; CLAY WC; KILPATRICK K; ONORI J; KOST T; EMERSON DL
      INHIBITION OF ESTABLISHMENT OF PRIMARY AND MICROMETASTATIC TUMORS BY A UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR ANTAGONIST

      Clinical & experimental metastasis
    72. Gruner, BA; Weitman, SD
      The folate receptor as a potential therapeutic anticancer target

      INVESTIGATIONAL NEW DRUGS
    73. MARKMAN M; KENNEDY A; WEBSTER K; KULP B; PETERSON G; BELINSON J
      LOW-DOSE ORAL GRANISETRON (1 MG) PLUS INTRAVENOUS DEXAMETHASONE - EFFICACY IN GYNECOLOGIC CANCER-PATIENTS RECEIVING CARBOPLATIN-BASED CHEMOTHERAPY

      Gynecologic oncology (Print)
    74. PRONZATO P; LIONETTO R; BOTTO F; PENSA F; TOGNONI A
      HIGH-DOSE INTENSITY CYCLOPHOSPHAMIDE, EPIDOXORUBICIN, VINCRISTINE ANDPREDNISONE BY SHORTENED INTERVALS AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN NON-HODGKINS-LYMPHOMA - A PHASE-II STUDY

      British Journal of Cancer
    75. AABO K; ADAMS M; ADNITT P; ALBERTS DS; ATHANAZZIOU A; BARLEY V; BELL DR; BIANCHI U; BOLIS G; BRADY MF; BRODOVSKY HS; BRUCKNER H; BUYSE M; CANETTA R; CHYLAK V; COHEN CJ; COLOMBO N; CONTE PF; CROWTHER D; EDMONSON JH; GENNATAS C; GILBEY E; GORE M; GUTHRIE D; KAYE SB; LAING AH; LANDONI F; LEONARD RC; LEWIS C; LIU PY; MANGIONI C; MARSONI S; MEERPOHL H; OMURA GA; PARMAR MKB; PATER J; PECORELLI S; PRESTI M; SAUERBREI W; SKARLOS DV; SMALLEY RV; SOLOMON HJ; STEWART LA; STURGEON JFG; TATTERSALL MHN; WHARTON JT; HUININK WWT; TOMIROTTI M; TORRI W; TROPE C; TURBOW MM; VERMORKEN JB; WEBB MJ; WILBUR DW; WILLIAMS CJ; WILTSHAW E; YEAP BY
      CHEMOTHERAPY IN ADVANCED OVARIAN-CANCER - 4 SYSTEMATIC METAANALYSES OF INDIVIDUAL PATIENT DATA FROM 39 RANDOMIZED TRIALS

      British Journal of Cancer
    76. SUGIYAMA T; YAKUSHIJI M; NISHIDA T
      COMBINATION OF CPT-11 WITH CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN-CANCER - REPORT OF 2 CASES

      Oncology Reports
    77. MCVIE JG
      RESPONSE RATE, SURVIVAL OR OTHER END-POINTS - A SCIENTIFIC DEBATE - PROCEEDINGS OF A SATELLITE MEETING AT THE 19TH CONFERENCE AT ESMO, LISBON, NOVEMBER 1994 - CHAIRMANS INTRODUCTION

      European journal of cancer
    78. TROPE C; KAERN J; KRISTENSEN G; ROSENBERG P; SORBE B
      PACLITAXEL IN UNTREATED FIGO STAGE-III SUBOPTIMALLY RESECTED OVARIAN-CANCER

      Annals of oncology
    79. YU WD; CHANG MJ; TRUMP DL; JOHNSON CS
      INTERLEUKIN-1-ALPHA SYNERGISTIC IN-VIVO ENHANCEMENT OF CYCLOPHOSPHAMIDE-MEDIATED AND CARBOPLATIN-MEDIATED ANTITUMOR-ACTIVITY

      Cancer immunology and immunotherapy
    80. DUFFULL SB; ROBINSON BA
      CLINICAL PHARMACOKINETICS AND DOSE OPTIMIZATION OF CARBOPLATIN

      Clinical pharmacokinetics
    81. PRONZATO P; PENSA F; VAIRA F; VIGANI A
      GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTORS IN LOW-DOSES AND INTENSITY OF CHEMOTHERAPY

      Tumori
    82. COLOZZA M; MOSCONI AM; GORI S; BELSANTI V; BASURTO C; DEANGELIS V; GIANSANTI M; TONATO M
      LONG-TERM RESULTS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CARCINOMA TREATED WITH A COMBINATION OF CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE

      American journal of clinical oncology
    83. NAKANISHI R; KUME T; MITSUDOMI T; YOSHIMATSU T; OSAKI T; TOKUNAGA H; YASUMOTO K
      COMBINED CARBOPLATIN AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER

      American journal of clinical oncology
    84. MIGLIETTA L; AMOROSO D; BRUZZONE M; GRANETTO C; CATSAFADOS E; MAMMOLITI S; GUARNERI D; PEDULLA F; FOGLIA G; RAGNI N; MARTINI MC; BREMA F; ADDAMO G; MORAGLIO L; PASTORINO G; BOCCARDO F
      PACLITAXEL PLUS IFOSFAMIDE IN ADVANCED OVARIAN-CANCER - A MULTICENTERPHASE-II STUDY

      Oncology
    85. HILKENS PHE; PRONK LC; VERWEIJ J; VECHT CJ; VANPUTTEN WLJ; VANDENBENT MJ
      PERIPHERAL NEUROPATHY INDUCED BY COMBINATION CHEMOTHERAPY OF DOCETAXEL AND CISPLATIN

      British Journal of Cancer
    86. CHOLLET P; BENSMAINE MA; BRIENZA S; DELOCHE C; CURE H; CAILLET H; CVITKOVIC E
      SINGLE-AGENT ACTIVITY OF OXALIPLATIN IN HEAVILY PRETREATED ADVANCED EPITHELIAL OVARIAN-CANCER

      Annals of oncology
    87. BUSER K; BACCHI M; GOLDHIRSCH A; GREINER R; DIENER P; SESSA C; JUNGI WF; FORNI M; LEYVRAZ S; ENGELER V
      TREATMENT OF OVARIAN-CANCER WITH SURGERY, SHORT-COURSE CHEMOTHERAPY AND WHOLE ABDOMINAL RADIATION

      Annals of oncology
    88. BUYSE M; PIEDBOIS P
      ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL-TIME

      Statistics in medicine
    89. BOTTALICO C; LORUSSO V; BRANDI M; MICELLI G; RELLA C; COVIELLO M; ATLANTE AM; QUARANTA M; DELENA M
      CORRELATION BETWEEN HPLC-DETERMINED LONIDAMINE SERUM LEVELS AND CLINICAL-RESPONSE IN PATIENTS WITH ADVANCED OVARIAN-CANCER

      Anticancer research
    90. CAVALETTI G; CASCINU S; VENTURINO P; TEDESCHI M; TREDICI G
      NEUROPROTECTANT DRUGS IN CISPLATIN NEUROTOXICITY

      Anticancer research
    91. NATOLI C; SALINI V; IRTELLI L; MARTINO MT; GARUFI C; GRASSADONIA A; FIORENTINO B; IACOBELLI S
      A PHASE-I STUDY OF 5-DAY CONTINUOUS VENOUS INFUSION OF CARBOPLATIN ATCIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE

      Anticancer research
    92. COLLEONI M; BONI L; VICARIO G; PANCHERI F; SGARBOSSA G; NELLI P; CALABRO F; TONIOLO L; BORTOLOTTI L; MANENTE P
      A DOSE-ESCALATING STUDY OF CARBOPLATIN COMBINED WITH VINORELBINE IN NON-SMALL-CELL LUNG-CANCER

      Oncology
    93. BERTELSEN K; KRUHOFFER A
      WHAT HAVE WE ACHIEVED IN OVARIAN-CANCER - A COMPARISON OF SURVIVALS AND RESOURCES IN 2 DIFFERENT PERIODS

      International journal of gynecological cancer
    94. DREES N; DENGLER WM; HENDRIKS HR; KELLAND LR; FIEBIG HH
      CYCLOPLATAM - A NOVEL PLATINUM COMPOUND EXHIBITING A DIFFERENT SPECTRUM OF ANTITUMOR-ACTIVITY TO CISPLATIN

      European journal of cancer
    95. ALBERTS DS; NOEL JK
      CISPLATIN-ASSOCIATED NEUROTOXICITY - CAN IT BE PREVENTED

      Anti-cancer drugs
    96. NICOLETTO MO; PADRINI R; KOUSSIS H; ROSABIAN A; AVERSA S; ENDRIZZI L; AZZONI P; PALUMBO M; FIORENTINO MV
      CONTINUOUS MITOXANTRONE INFUSION IN PRETREATED EPITHELIAL OVARIAN-CANCER

      Cancer chemotherapy and pharmacology
    97. VANDIEST PJ; ZEVERING JP; ZEVERING LC; BAAK JPA
      PROGNOSTIC VALUE OF MICROVESSEL QUANTITATION IN CISPLATIN-TREATED FIGO-3 AND FIGO-4 OVARIAN-CANCER PATIENTS

      Pathology research and practice
    98. MANETTA A; BLESSING JA; LOOK KY
      PHASE-II STUDY OF FAZARABINE IN PATIENTS WITH ADVANCED OVARIAN-CANCER- A GYNECOLOGIC-ONCOLOGY-GROUP STUDY

      American journal of clinical oncology
    99. VANWARMERDAM LJC; RODENHUIS S; HUININK WWTB; MAES RAA; BEIJNEN JH
      THE USE OF THE CALVERT FORMULA TO DETERMINE THE OPTIMAL CARBOPLATIN DOSAGE

      Journal of cancer research and clinical oncology
    100. BENDAVID Y; ROSEN B; FRANSSEN E; EINARSON T; SZYFER I
      METAANALYSIS COMPARING CISPLATIN TOTAL-DOSE INTENSITY AND SURVIVAL

      Gynecologic oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 18:44:50